Taiwan Liposome Company Ltd ADR
NASDAQ:TLC (9/28/2021, 7:00:01 PM)
7
0 (0%)
Taiwan Liposome Company Ltd. is a specialty pharmaceutical company. It focuses on development and commercialization of novel nanomedicines designed to target unmet medical need in pain management, ophthalmology and oncology. The company's product pipeline consists of TLC599, TLC590, TLC399 and TLC178 which are in clinical stage. Taiwan Liposome Company Ltd. is headquartered in Taipei City, Taiwan.
Taiwan Liposome Company Ltd ADR
11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT
TAIPEI CITY F5 11503
P: 886-2-2655-7377
CEO: Keelung Hong
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the...
Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks
Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks...
One of the largest deals seen in Taiwan’s biotech sector...
TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication...
Here you can normally see the latest stock twits on TLC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: